Extracting antipsychotic polypharmacy data from electronic health records: Developing and evaluating a novel process

BMC Psychiatry

Volumn 15, Issue 1, 2015, Pages

  Kadra, Giouliana ^a   Stewart, Robert ^a,b   Shetty, Hitesh ^b   Jackson, Richard G ^a,b   Greenwood, Mark A ^c   Roberts, Angus ^c   Chang, Chin Kuo ^a   MacCabe, James H ^a,b   Hayes, Richard D ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Antipsychotic polypharmacy; Electronic health records; Precision; Recall

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERICIAZINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SULPRIDE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; ZUCLOPENTHIXOL;

ACCURACY; ANTIPSYCHOTIC POLYPHARMACY; ARTICLE; BIPOLAR DISORDER; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; DRUG INFORMATION; ELECTRONIC MEDICAL RECORD; GOLD STANDARD; HUMAN; LANGUAGE PROCESSING; LEARNING ALGORITHM; MEDICAL RESEARCH; MENTAL DISEASE; MENTAL HEALTH CARE; MONOTHERAPY; PATIENT CARE; POLYPHARMACY; PRESCRIPTION; PREVALENCE; RECALL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SERIOUS MENTAL ILLNESS; TREATMENT DURATION; TREATMENT OUTCOME; UNITED KINGDOM; VALIDITY; ADULT; CLINICAL PRACTICE; ELECTRONIC HEALTH RECORD; ENGLAND; EVALUATION STUDY; MENTAL DISORDERS; STANDARDS; STATISTICS AND NUMERICAL DATA;

ADULT; ANTIPSYCHOTIC AGENTS; ELECTRONIC HEALTH RECORDS; HUMANS; LONDON; MENTAL DISORDERS; POLYPHARMACY; PRACTICE PATTERNS, PHYSICIANS'; PREVALENCE;

EID: 84937691425     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/s12888-015-0557-z     Document Type: Article

References (36)

1. Munk-Jørgensen P, Okkels N, Golberg D, Ruggeri M, Thornicroft G. Fifty years' development and future perspectives of psychiatric register research. Acta Psychiatr Scand. 2014;130(2):87-98.
2. Amaddeo F. The small scale clinical psychiatric case registers. Acta Psychiatr Scand. 2014;130(2):80-2.
3. Stewart R. The big case register. Acta Psychiatr Scand. 2014;130(2):83-6.
4. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin B. Prevalence, trends, and factors associated with antipsychotic polypharmacy among medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry. 2004;65(10):1-12.
5. Taylor D, Mace S, Mir S, Kerwin R. A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom. Int J Psychiatry Clin Pract. 2003;4:1-6.
6. Leckman-Westin E, Kealey E, Gupta N, Chen Q, Gerhard T, Crystal S, et al. Validation of a claims-based antipsychotic polypharmacy measure. Pharmacoepidemiol Drug Saf. 2014;23:628-35.
7. Taylor D, Mace S, Mir S, Kerwin R. A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom. Int J Psychiatry Clin Pract. 2000;4:41-6.
8. Su Y-P, Chang C-K, Hayes RD, Harrison S, Lee W, Broadbent M, et al. Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatr Scand. 2014;130(1):52-60.
9. Centorrino F, Cincotta SL, Talamo A, Fogarty KV, Guzzetta F, Saadeh MG, et al. Hospital use of antipsychotic drugs: polytherapy. Compr Psychiatry. 2008;49(1):65-9.
10. Brown S, Barraclough B, Inskip H. Causes of the excess mortality of schizophrenia. Br J Psychiatry. 2000;177(3):212-7.
11. Suzuki T, Uchida H, Watanabe K, Nakajima S, Nomura K, Takeuchi H, et al. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. Hum Psychopharmacol Clin Exp. 2008;23(6):455-63.
12. Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ. Multiple Versus Single Antipsychotic Agents for Hospitalized Psychiatric Patients: Case-Control Study of Risks Versus Benefits. Am J Psychiatry. 2004;161:1-7.
13. Meystre SM, Savova GK, Hurdle JF. Extracting Information from Textual Documents in the Electronic Health Record: A Review of Recent Research. IMIA Yearb Med Informatics. 2008;1:128-44.
14. Uzuner O, Solti I, Cadag E. Extracting medication information from clinical text. J Am Med Inform Assoc. 2010;17(5):514-8.
15. Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU. Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012;138(1):18-28.
16. van Bennekom MW L, Gijsman HJ, Zitman FG. Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness. J Psychopharmacol. 2013;27(4):327-36.
17. Chang C-K, Hayes RD, Broadbent M, Fernandes AC, Lee W, Hotopf M, et al. All-cause mortality among people with serious mental illness (SMI), substance use disorders, and depressive disorders in southeast London: a cohort study. BMC Psychiatry. 2010;10(1):77.
18. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms. Pharmacol Ther. 2010;125(1):169-79.
19. Brown S. Excess mortality of schizophrenia. A meta-analysis Br J Psychiatry. 1997;171(6):502-8.
20. Stewart R, Soremekun M, Perera G, Broadbent M, Callard F, Denis M, et al. The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: development and descriptive data. BMC Psychiatry. 2009;9(1):51.
21. Cunningham H, Tablan V, Roberts A, Bontcheva K. Getting more out of biomedical documents with GATE's full lifecycle open source text analytics. PLoS Comput Biol. 2013;9(2), e1002854.
22. Correll CU, Shaikh L, Gallego JA, Nachbar J, Olshanskiy V, Kishimoto T, et al. Antipsychotic polypharmacy: A survey study of prescriber attitudes, knowledge and behavior. Schizophr Res. 2011;131(1-3):58-62.
23. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Metaanalysis of Randomized Controlled Trials. Schizophr Bull. 2009;35(2):443-57.
24. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-62.
25. Hayes RD, Downs J, Chang C-K, Jackson RG, Shetty H, Broadbent M, et al. The Effect of Clozapine on Premature Mortality: An Assessment of Clinical Monitoring and Other Potential Confounders. Schizophr Bull. 2014;41(3):644-55.
26. Morrato EH, Dodd S, Oderda G, Haxby DG, Allen R, Valuck RJ. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003. Clin Ther. 2007;29(1):183-95.
27. Jaffe AB, Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Saf. 2003;12(1):41-8.
28. Broekema WJ, Groot IW, Harten PN. Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics-a European study. Pharm World Sci. 2007;29(3):126-30.
29. Taylor D, Mir S, Mace S, Whiskey E. Co-prescribing of atypical and typical antipsychotics -- prescribing sequence and documented outcome. Psychiatr Bull. 2002;26(5):170-2.
30. Suokas JT, Suvisaari JM, Haukka J, Korhonen P, Tiihonen J. Description of long-term polypharmacy among schizophrenia outpatients. Soc Psychiatry Psychiatr Epidemiol. 2012;48(4):631-8.
31. Centorrino F, Fogarty KV, Sani G, Salvatore P, Cincotta SL, Hennen J, et al. Use of combinations of antipsychotics: McLean Hospital inpatients, 2002. Hum Psychopharmacol Clin Exp. 2005;20(7):485-92.
32. Ganguly R, Kotzan JA, Miller LS. Long term antipsychotic polypharmacy is common among Medicaid recipients with schizophrenia. Evid Based Ment Health. 2005;8(2):55.
33. Bernardo M, Coma A, Ibáñez C, Zara C, Bari JM, Serrano-Blanco A. Antipsychotic polypharmacy in a regional health service: a populationbased study. BMC Psychiatry. 2012;12(1):42.
34. Taylor DM, Smith L, Gee SH, Nielsen J. Augmentation of clozapine with a second antipsychotic - a meta-analysis. Acta Psychiatr Scand. 2011;125(1):15-24.
35. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand. 2002;106:1-8.
36. Lerner V, Libov I, Kotler M, Strous RD. Combination of "atypical" antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. Prog Neuro-Psychopharmacology Biol Psychiatry. 2004;28(1):89-98.